Results 21 to 30 of about 455,027 (266)

Dimethyl fumarate combined with cisplatin at subcytotoxic doses sensitizes cervical cancer toward ferroptosis and apoptosis through GSH restriction and p53 (re)activation

Molecular Oncology, EarlyView.
Dimethyl fumarate (DMF) reduces growth of HPV‐positive cervical cancer spheroids and induces ferroptosis in cervical cancer cells via blocking SLC7A11/Glutathione (GSH) axis. Combination of subcytotoxic doses of DMF and cisplatin (CDDP) further suppresses spheroid growth and drives cell death in 2D culture models.
Carolina Punziano, Giuseppina Minopoli, Simona Romano, Laura Marrone, Katia Aquilano, Maria Lina Tornesello, Raffaella Faraonio   +6 more
wiley   +1 more source

MicroRNA profiling in B cell non-Hodgkin Lymphoma : focus on the role of MYC [PDF]

, 2013
Non-Hodgkinlymfoon is een kwaadaardige vorm van kanker die uitgaat van de lymfeklieren. De ziekte wordt gekenmerkt door specifieke chromosoomafwijkingen en door afwijkende patronen van genexpressie.
Robertus, Jan Lukas,, Robertus, Jan Lukas   +1 more
core  

CD47 promotes mitogen‐activated protein kinase and epithelial‐to‐mesenchymal transition molecular programs to drive prometastatic phenotypes in non‐small cell lung cancer

Molecular Oncology, EarlyView.
Beyond its role in immune evasion, this study identified that CD47 drives tumor‐intrinsic signaling in non‐small cell lung cancer (NSCLC). Transcriptomic profiling and functional studies revealed that CD47 regulates cell adhesion, migration, and metastasis through an ERK–EMT signaling axis.
Asa P.Y. Lau, Lilian G. Zhai, Ryunosuke Hoshi, Zackary Rousseau, Abraam Zakhary, Yin Fang Wu, Rola M. Saleeb, Heyu Ni, Kelsie L. Thu   +8 more
wiley   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Characteristics of aggressive B-cell lymphoma [PDF]

, 2019
Aggressive B-cell lymphomas are a heterogeneous group of mature B-cell neoplasms with morphological similarities, but phenotypic and genetic differences.
Nijland, Marcel; id_orcid, Nijland, Marcel   +1 more
core   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Mechanisms of Rejection of High Grade B cell Lymphoma in Mice [PDF]

, 2008
The incidence of high grade B cell lymphoma in western countries has increased over the last decades. Improvement of conventional chemotherapy regimens has significantly contributed to prolonged 5-year survival rates which currently reach around 60 ...
Sukumar, Madhusudhanan
core  

Vitamin D3 receptor is highly expressed in Hodgkin's lymphoma

, 2012
Background: Hodkin s lymphoma is one of the most frequent lymphoma in western world. Despite an overall good prognosis some patients suffer relapsing tumors which are difficult to cure.
Renné Christoph, Benz Alexander H, Hansmann Martin L, Christoph, Renné, Benz, Alexander, Hansmann, Martin-Leo   +5 more
core   +1 more source

Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma [PDF]

, 2011
PURPOSE: This analysis from an observational study of clinical practice describes the impact of febrile neutropenia (FN) on chemotherapy delivery and hospitalizations.
Rossi, F G, Lugtenburg, P.J. (Pieternella), Pieternella J. Lugtenburg, Ulrich Dührsen, Bendall, K. (Kate), Dührsen, U. (Ulrich), Silvestre, AS, Francesca G. Rossi, Jaeger, U, Jaeger, Ulrich, Gaia Rossi, F. (Francesca), Matthias Schwenkglenks, Pettengell, R, Schwenkglenks, Matthias, Rossi, FG, Salar Silvestre, A, Dührsen, U, Szabo, C. (Csilla), Johnson, Hans E., Dührsen, Ulrich, Schwenkglenks, M, Bendall, Kate, Lugtenburg, PJ, Rossi, Francesca G, Hans E. Johnson, Rossi, Francesca G., Bendall, K, Jaeger, U. (Ulrich), Szabo, Z, Johnsen, HE, Silvestre, Antonio Salar, Johnson, H.E. (Hans), Pettengell, Ruth, Lugtenburg, Pieternella J., Lugtenburg, Pieternella J, Zsolt Szabo, Ruth Pettengell, Johnsen, Hans E, Szabo, Zsolt, Silvestre, J.S. (Jean Sebastien), Schwenkglenks, M. (Matthias), Pettengell, R. (Ruth), Antonio Salar Silvestre, Ulrich Jaeger, Johnson, H E, Lugtenburg, P J, Kate Bendall   +46 more
core   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source